Skip to main content

Staphylococcus Aureus

4
Pipeline Programs
12
Companies
11
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
2
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

12 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
1
Mupirocin calcium ointment, 2%Phase 4
ARTHR-IS (Arthroplasties' Infections Due to Staphylococcus Aureus)N/A
MSD
MSDIreland - Ballydine
1 program
1
V710Phase 2/31 trial
Active Trials
NCT00518687Terminated8,031Est. Aug 2011
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
V710Phase 2/3
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD7760Phase 1/21 trial
Active Trials
NCT06749457Recruiting231Est. Sep 2027
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
Network on Antimicrobial Resistance in Staphylococcus AureusN/A1 trial
nasal microbiota transplantPHASE_11 trial
Active Trials
NCT00341913CompletedEst. Jun 2008
NCT05695196Active Not Recruiting34Est. Dec 2026
GSK
GSKLONDON, United Kingdom
1 program
ARTHR-IS (Arthroplasties' Infections Due to Staphylococcus Aureus)N/A1 trial
Active Trials
NCT03826108Unknown600Est. Dec 2020
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Antimicrobial Drug Use and Resistant Staphylococcus AureusN/A1 trial
Active Trials
NCT01075451Completed41Est. May 2013
Solventum
SolventumMN - St. Paul
1 program
Evaluation of a Diagnostic Device for Detection of Nasal Staphylococcus AureusN/A1 trial
Active Trials
NCT00406549Completed2,000Est. Mar 2007
Pfizer
PfizerNEW YORK, NY
1 program
Staphylococcus Aureus Surgical Site Infection Multinational Epidemiology in EuropeN/A1 trial
Active Trials
NCT03353532Completed178,902Est. Jan 2021
Astellas
AstellasChina - Shenyang
1 program
The Causes and Interpretation of Low-level Resistance in Staphylococcus AureusN/A1 trial
Active Trials
NCT01127516Completed45Est. May 2013
Parexel
ParexelMA - Boston
1 program
AZD7760PHASE_1_2
Bristol Myers Squibb
1 program
Aurexis®PHASE_22 trials
Active Trials
NCT00198302Completed60Est. Feb 2005
NCT00198289Completed30Est. Jun 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
MSDV710
Bristol Myers SquibbAurexis®
Bristol Myers SquibbAurexis®
AstraZenecaAZD7760
Allergy Therapeuticsnasal microbiota transplant
GSKARTHR-IS (Arthroplasties' Infections Due to Staphylococcus Aureus)
PfizerStaphylococcus Aureus Surgical Site Infection Multinational Epidemiology in Europe
AstellasThe Causes and Interpretation of Low-level Resistance in Staphylococcus Aureus
Merck & Co.Antimicrobial Drug Use and Resistant Staphylococcus Aureus
SolventumEvaluation of a Diagnostic Device for Detection of Nasal Staphylococcus Aureus
Allergy TherapeuticsNetwork on Antimicrobial Resistance in Staphylococcus Aureus

Clinical Trials (11)

Total enrollment: 189,974 patients across 11 trials

NCT00518687MSDV710

Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)

Start: Dec 2007Est. completion: Aug 20118,031 patients
Phase 2/3Terminated
NCT00198302Bristol Myers SquibbAurexis®

Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)

Est. completion: Feb 200560 patients
Phase 2Completed
NCT00198289Bristol Myers SquibbAurexis®

Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs

Start: Apr 2005Est. completion: Jun 200630 patients
Phase 2Completed
NCT06749457AstraZenecaAZD7760

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

Start: Dec 2024Est. completion: Sep 2027231 patients
Phase 1/2Recruiting
NCT05695196Allergy Therapeuticsnasal microbiota transplant

Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant

Start: Oct 2023Est. completion: Dec 202634 patients
Phase 1Active Not Recruiting
NCT03826108GSKARTHR-IS (Arthroplasties' Infections Due to Staphylococcus Aureus)

ARTHR-IS (Arthroplasties' Infections Due to Staphylococcus Aureus)

Start: Apr 2019Est. completion: Dec 2020600 patients
N/AUnknown
NCT03353532PfizerStaphylococcus Aureus Surgical Site Infection Multinational Epidemiology in Europe

Staphylococcus Aureus Surgical Site Infection Multinational Epidemiology in Europe

Start: Aug 2017Est. completion: Jan 2021178,902 patients
N/ACompleted
NCT01127516AstellasThe Causes and Interpretation of Low-level Resistance in Staphylococcus Aureus

The Causes and Interpretation of Low-level Resistance in Staphylococcus Aureus

Start: Apr 2010Est. completion: May 201345 patients
N/ACompleted
NCT01075451Merck & Co.Antimicrobial Drug Use and Resistant Staphylococcus Aureus

Antimicrobial Drug Use and Resistant Staphylococcus Aureus

Start: Jan 2010Est. completion: May 201341 patients
N/ACompleted
NCT00406549SolventumEvaluation of a Diagnostic Device for Detection of Nasal Staphylococcus Aureus

Evaluation of a Diagnostic Device for Detection of Nasal Staphylococcus Aureus

Start: Dec 2006Est. completion: Mar 20072,000 patients
N/ACompleted
NCT00341913Allergy TherapeuticsNetwork on Antimicrobial Resistance in Staphylococcus Aureus

Network on Antimicrobial Resistance in Staphylococcus Aureus

Start: Mar 2000Est. completion: Jun 2008
N/ACompleted

Related Jobs

Automation Infrastructure Engineer

RegeneronRegeneron
Limerick
3mo ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 189,974 patients
12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.